February 26, 2018 5:27pm

Sector opened up, was barely positive at the mid-day and1:30 p.m. was the advent of a witching downturn closing barely to the upside

 

Volume and advance/decline lines deteriorate with more volatility on the horizon

Pre-open indication results: 3 hits and 3 miss (made a buck selling into strength in 2)

Out and about: MiMedx Group (MDXG -$0.48) continues to slip with 23.9 M shares traded <3 month average = 2.59 M shares> while under federal investigation related to business practices falling -6.13% to a more than three year and a half year low in the trading range of $6.05 to $8.00 to close at $7.35.

 

Review my daily “Sudoku” of indicators, factors, trend lines, advance/decline lines of 40 covered companies, pre-open indicator results, volatility and analytics of the % count of decliners versus gainers with a few surprises in the shifting sands of appreciation or depreciation


 

Monday’s results have implications to Tuesday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

 

Henry’omics:

From the pre-open’s newsletter, “…living on borrowed pricing? Three (3) positive closes in a row, the machines are “algorithming” and maybe a fourth (4th)? However, volatility matters and its swings when the weekly gains outstrip the fundamentals and technicals; the sector may come to understand its vulnerabilities or maybe not although the inevitable is the downside.”

There is a sense that today’s move to the upside was overdue yet would contribute to a decline in the ensuing sessions!

Is there a “Sudoku” concept to all these indicators, factors and trend lines – a tale of which story for tomorrow?

That’s why I focus on the daily “sector” puzzle!

 

 

Pre-open indication results:  3 hits and 3 miss

  • Adverum (ADVM) closed down -$0.30 – hit;
  • AxoGen (AXGN) closed up +$0.55 – miss;
  • bluebird bio (BLUE) closed down -$4.90 – hit;
  • Fate Therapeutics (FATE) closed up +$0.30 – miss;
  • Caladrius Bioscience (CLBS) closed up +$0.28 – miss;
  • MiMedx (MDXG) closed down -$0.48 – miss;
  • Stemline Therapeutics (STML) closed down -$0.20 – hit;

 

 

The shifting sands of appreciation and depreciation:

The come-back sector stocks: AST (+$0.05), HSGX (+$0.03), ONVO (+$0.04), VSTM (+$0.01) and VCEL (+$0.80 – something is going-on)

While the downers: ADRO (-$0.05), ADVM (-$0.30), ATHX (-$0.02), BLFS (-$0.04), CLLS (-$0.20), XON (-$0.12) OSIR (-$0.45), STML (-$0.20), and especially BLUE (-$4.90),

Surprised by BLCM (+$0.25), FATE (+0.30), CLBS ($0.28), QURE (+$0.21) and AXGN (+$0.30)

Flat: AGTC ($0.00),

Sliding: CAPR (+$0.01) post news

Going nowhere: BSTG (-$0.05), FCSC (+$0.0028), KOOL (+$0.00 – on news) and BCLI (-$0.10) and NWBO ($0.00),

 

 

The advance/decline line scenario of 40 SCGT & RT covered companies:   

·         The open was positive with an A/DL of 23/15 and 2 flat ;

·         The mid-day was positive with an A/DL of 21/18 and 1 flat;

·         1:30 p.m. slipped negative with an A/DL of 16/20 and 4 flats;

·         The close was positive  with an A/DL of 20/17 and 3 flat;

 

 

MY working trend lines:

The greatest volume to the downside:  MDXG, ADVM, XON, ATHX and CYTX

Upside volume was weighted to:  JUNO, ONCE, FATE, VCEL and NWBO

Biggest $ downside:  BLUE (-$4.90), RENE.L (-$0.50), MDXG (-$0.48), OSIR (-$0.45) and ADVM (-$0.30)

Largest $ upside:  ONCE (+$4.82), MESO (+$1.11), RGNX (+$0.82), VCEL (+$0.80) and AXGN (+$0.55)

Flat:  AGTC, KOOL and SGMO

 

 

Daily analytics:

The Dow and S&P 500 rose for a third session Monday in a broad-based rally led by technology shares on the back of rotational buying.

·         The Dow rose 399.28 points, or 1.6%, to 25,709.27.

·         The S&P 500 index climbed 32.30 points, or 1.2%, to 2,779.60.

·         The NASDAQ added 84.07 points, or 1.2%, to 7,421.46.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market,

  • Monday traded at 15.80, down -4.18% …

·         Friday traded at 16.64, down -11.11% …

·         Thursday traded at 18.72, down -6.49% …

·         Wednesday traded at 20.22, down -2.82% …

·         Tuesday traded at 20.60, up +5.86% …

·         Last Monday was a market holiday

 

The iShares Russell 2000 (IWM) indicated:

·         Monday was up +0.64%

·         Friday +1.30%

·         Thursday -0.15%

·         Wednesday +0.09%

·         Tuesday -0.83%

·         Last Monday was a market holiday

 

The iShares NASDAQ Biotechnology (IBB) indicated:

·         Monday was up +0.73%

·         Friday +2.08%

·         Thursday -0.61%

·         Wednesday -0.16%

·         Tuesday -1.01%

·         Last Monday was a market holiday

 

 

The count - decliners versus gainers:

……. look at the differences in decliners:

·         Monday’s decliners ranged from -0.51% <RENE.L -$0.50> to -6.13% <MDXG -$0.48> in 17 equities;

·         Friday’s decliners ranged from -0.34% <CLLS -$0.11> to -11.82% <MDXG -$1.05> in 17 equities;

·         Thursday’s decliners ranged from -0.09% <JUNO -$0.08> to -8% <FCSC -$0.053> in 10 equities;

·         Wednesday’s decliners ranged from -0.15% <BSTG -$0.00> to -10.63% <RENE.L> in 13 equities;

·         Tuesday’s decliners ranged from -0.14% <JUNO -$0.12> to -39.53% <MDXG -$5.72> in 26 equities;

·         Last Monday was a market holiday

Versus

… Look at the percentage’s (%) and spreads …

·         Monday’s gainers ranged from +0.02% <JUNO +$0.02> to +17.93% <MESO +$1.11> in 20 equities;

·         Friday’s gainers ranged from +0.02% <JUN) +$0.02> to +11.15% <FATE +$1.18> in 21 equities;

·         Thursday’s gainers ranged from +0.15% <CLLS +$0.05> to +14.41% <SGMO +$3.20> in 28 equities;

·         Wednesday’s gainers ranged from +0.08% <XON +0.01> to +15.49% <FATE +$1.42> in 24 equities;

·         Tuesday’s gainers ranged from +0.39% <FCSC +$0.0026> to +4.70% <BLCM +$0.31> in 12 equities;

·         Last Monday was a market holiday;

 

                                 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.